Here's a look at some of the noteworthy HIV research being presented at IDWeek 2016 in New Orleans from Oct. 25 to 30.
"Modern ART is likely to retain viral suppression with significantly less than 100% adherence," Simon Collins writes. "The results might therefore reduce anxiety associated with missed occasional missed doses in someone who otherwise has a good histo...
Beyond Cervical Cancer: Patterns and Treatment of Gynecologic Malignancies Among Women Living With HIV
With HIV-positive women living longer, cancer epidemiologist Anne F. Rositch, Ph.D., looked at contemporary trends, patterns of disease, adherence to national care guidelines and barriers to treatment of non-HPV-associated gynecologic malignancies....
Community-based participatory research (CBPR) is an approach that can address social determinants of health by iinterrupting cycles of powerlessness in vulnerable communities.
A follow-up analysis from LATTE-2 showed that most participants generally favored an injectable HIV regimen to taking daily pills, with many stating that it helped with stigma.
If We Act to Remove Structural, Behavioral and Social Barriers, We Can End the HIV Epidemic With the Medicines We Already Have
Benjamin Young, M.D., Ph.D., discusses the need to change perceptions of HIV harm, the role of providers as activists and his work updating the global knowledge base to reflect the 21st-century realities of HIV.
A four-day-per-week treatment regimen maintained undetectable viral loads in 96 of 100 participants of a 48-week study.
Results from the first proof-of-principle for injection-only HIV treatment (ART) were presented at AIDS 2016.
Dolutegravir-based ART was superior to a boosted atazanavir-based regimen in treatment naive women at 48 weeks, according to data from the ARIA study presented at AIDS 2016.
Nanoparticles containing elvitegravir, emtricitabine and tenofovir alafenamide (EVG/FTC/TAF) suppressed HIV when injected into humanized mice. Viral loads remained undetectable three weeks after the last dose.